Oncolytic Virus Immunotherapy Market – By Virus Type (HSV, Adenovirus, Vaccinia Virus, Reovirus), Application (Melanoma, Breast Cancer, Prostate Cancer), Route of Administration (Intratumoral, Intravenous), End-user – Global Forecast 2024 – 2032

Oncolytic Virus Immunotherapy Market Size

Oncolytic Virus Immunotherapy Market size was valued at USD 306.2 million in 2023 and is expected to grow at a CAGR of 22.6% between 2024 and 2032, due to the increasing incidence of cancer worldwide, which necessitated the development of novel and effective treatment options.
 

According to the International Agency for Research on Cancer (IARC) estimation in 2022, around 20 million new cancer cases and 9.7 million deaths were estimated. The report also stated the projection figures of 35 million new cases by 2050, up 77% from 2022. Thus, the escalating global cancer burden is expected to surge the demand for innovative therapies. thereby propelling the market growth in the future.
 

Oncolytic virus immunotherapy is a cancer treatment approach that utilizes genetically modified viruses to selectively infect and destroy cancer cells while stimulating the immune system to recognize and attack tumors. These oncolytic viruses are engineered to replicate within cancer cells, leading to their destruction, and triggering an immune response against tumor antigens, potentially resulting in tumor regression and long-term anti-cancer immunity.
 

Oncolytic Virus Immunotherapy Market Trends

• Oncolytic virus immunotherapy has emerged as a promising therapy in cancer treatment, with numerous pharmaceutical companies focusing on research efforts and conducting clinical studies, combining oncolytic viruses with immune checkpoint inhibitors showing significant efficacy. The potential synergies between oncolytic virus immunotherapy and other treatments such as checkpoint inhibitors, chemotherapy, and radiotherapy are driving interest in combination therapies, enhancing efficacy and expanding the market opportunities.
   
• According to the National Cancer Institute, a study by Moffitt Cancer Center demonstrated that integrating an oncolytic virus talimogene laherparepvec (TVEC) with systemic chemotherapy could enhance responses in high-risk early-stage triple-negative breast cancer.
   

Oncolytic Virus Immunotherapy Market Analysis

Based on the virus type, the market is classified into herpes simplex virus (HSV), adenovirus, vaccinia virus, Newcastle disease virus, reovirus, and other virus types. The HSV segment has asserted its dominance in the global market by securing a significant share and experiencing growth of 22.7% between 2024 – 2032.
 

• The inherent properties of HSV have positioned it as a highly effective candidate for cancer immunotherapy demonstrating oncolytic capabilities by specifically infecting and replicating within cancer cells while leaving healthy tissue unaffected.
   
• Furthermore, genetic modifications can enhance HSV's tumor-targeting and immune-stimulating capabilities. With its versatility, safety, and proven efficacy in preclinical and clinical studies, HSV stands as a leading oncolytic virus in immunotherapy, consolidating its dominance in cancer treatments.

Based on the route of administration, the oncolytic virus immunotherapy market is classified into intratumoral, intravenous, and other routes of administration. The intravenous segment held the largest business share of 53% in 2023.
 

• Intravenous administration of oncolytic viruses represents a highly effective approach for treating metastatic cancers. The delivery ensures superior systemic bioavailability, enabling targeted distribution to potential metastatic sites throughout the body in comparison to the intratumoral route. This maximizes the reach of oncolytic viruses, enhancing their ability to combat disseminated cancer cells and metastases.
   
• Thus, intravenous administration stands out as a preferred method for delivering oncolytic viruses in the treatment of metastatic cancers, offering broader therapeutic coverage and potential clinical benefits.
   

Based on the application, the global oncolytic virus immunotherapy market is categorized into melanoma, breast cancer, lung cancer, ovarian cancer, prostate cancer, and other applications. The melanoma segment is expected to reach USD 713.5 million by 2032.
 

• Melanoma holds unique characteristics that make it particularly susceptible to oncolytic virus therapy, such as a high mutation burden and an immunogenic tumor microenvironment. Melanoma of the skin ranks as the 17th most prevalent cancer globally. In the U.S., the American Cancer Society projects approximately 100,640 new cases of melanoma to be diagnosed in 2024. This has anticipated the need for effective melanoma treatment.
   
• Additionally, the success of oncolytic viruses like Talimogene laherparepvec (T-VEC) in clinical trials for melanoma treatment has garnered significant attention and adoption.
   
• Furthermore, the limited efficacy of conventional therapies in advanced melanoma patients has created a strong demand for innovative treatment options, thereby driving the prominence of oncolytic virus immunotherapy in melanoma management.
   

Based on the end-user, the oncolytic virus immunotherapy market is classified into hospitals & clinics, cancer research institutes, ambulatory surgical centers, and other end-users. The hospitals & clinics segment accounted for 39.1% market share in 2023 and is expected to reach USD 735.1 million by 2032.
 

• Hospitals play a central role in serving as primary treatment centers for cancer patients. Availability of advanced facilities and specialized oncology departments, the hospitals facilitate the administration of oncolytic virus therapies, including diagnosis, treatment planning, and patient care.
   
• Their multidisciplinary approach, access to cutting-edge technologies, and collaboration with research institutions enable hospital & clinics to lead advancements in oncolytic virus immunotherapy, making them pivotal segment in the market.

North America region is projected to maintain its lead in the global oncolytic virus immunotherapy market, anticipated to exhibit 22.3% CAGR during the analysis period.
 

• North America is poised to maintain a significant dominance due to its growing patient population and rising cancer incidences. According to the American Cancer Society's 2021 report, the U.S. recorded approximately 1.9 million new cancer cases and 608,570 deaths in 2021.
   
• Similarly, according to the Centers for Medicare and Medicaid Services (CMS), increasing awareness of cancer treatments, the availability of advanced immune-oncology therapies, and rising healthcare spending reached nearly USD 4.1 trillion in 2020. Thus, rising healthcare expenditure, presence of key players in the region along with growing awareness pertaining to early diagnosis and treatment is expected to contribute to the market progress.
   

Oncolytic Virus Immunotherapy Market Share

The companies are actively prioritizing R&D efforts to pioneer novel therapies, broaden product portfolios, and fortify market presence. Strategic alliances, partnerships, and acquisitions are prevalent strategies to bolster competitiveness. Moreover, advancements in technology and escalating investments in oncology research are enhancing competition within the market.
 

Oncolytic Virus Immunotherapy Market Companies

Prominent players operating in the oncolytic virus immunotherapy industry are as mentioned below:

• Amgen Inc.
• Creative Biolabs
• Daiichi Sankyo Company Limited
• Genelux Corporation
• Oncorus Inc.
• Replimune Inc.
• Siga Technologies
• Sorrento Therapeutics Inc.
• TILT Biotherapeutics
• Viralytics Ltd.
   

Oncolytic Virus Immunotherapy Industry News:

• In September 2022, The University of Texas MD Anderson Cancer Center partnered with Virogin Biotech to expedite the advancement of investigational therapies, including the oncolytic viruses and immunotherapies, targeting advanced cancer patients. The collaboration aimed to pioneer novel treatment solutions, thereby strengthening their product pipeline.
   
• In June 2022, BioInvent International AB and Transgene joined forces with MSD, a subsidiary of Merck & Co., Inc., in a clinical trial collaboration and supply agreement. This collaboration aimed to assess the oncolytic virus BT-001 alongside MSD's anti-PD-1 therapy KEYTRUDA in a Phase 1/2a trial for solid tumor treatment. MSD will supply pembrolizumab for use in the ongoing trial, advancing the clinical development of the co-developed oncolytic candidate. This strategy enabled company to have a long-term business relation.
   

The oncolytic virus immunotherapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Virus Type

• Herpes simplex virus (HSV)
• Adenovirus
• Vaccinia virus
• Newcastle disease virus
• Reovirus
• Other virus types

Market, By Route of Administration

• Intratumoral
• Intravenous
• Other routes of administration

Market, By Application

• Melanoma
• Breast cancer
• Lung cancer
• Ovarian cancer
• Prostate cancer
• Other applications

Market, By End-user

• Hospitals & clinics
• Cancer research institutes
• Ambulatory surgical centers
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa